Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis

Nephrology Dialysis Transplantation

Volumn 16, Issue 11, 2001, Pages 2188-2193

  Goicoechea, Marian ^a   Caramelo, Carlos ^b,d   Rodriguez, Patrocinio ^a   Verde, Eduardo ^c   Gruss, Enrique ^a   Albalate, Marta ^a   Ortiz, Alberto ^b   Casado, Santos ^b   Valderrábano, Fernando ^c  

^a Section of Nephrology   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Anaemia; Native fistulate; Polytetrafluoroethylene (PTFE) graft

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALBUMIN; ANTITHROMBOCYTIC AGENT; ASPARTATE AMINOTRANSFERASE; DIPYRIDAMOLE; ERYTHROPOIETIN; FERRIC GLUCONATE; FERROUS SULFATE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; IRON; LACTATE DEHYDROGENASE; POLITEF; TARDYFERON; TICLOPIDINE;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG USE; ERYTHROCYTE TRANSFUSION; FOLLOW UP; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MEAN CORPUSCULAR VOLUME; POLITEF IMPLANT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VASCULAR ACCESS;

EID: 0035158863     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.11.2188     Document Type: Article

References (24)

1. Erythropoietin in chronic renal failure
2. Cardiovascular consequences of renal anaemia and erythropoietin therapy
3. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients
4. Meeting the challenges of a new millennium: Optimizing the use of recombinant human erythropoietin
5. R-HuEpo hyporesponsiveness - Who and why?
6. Iron status in patients receiving erythropoietin for dialysis-associated anemia
7. Effect of serum parathyroid hormone on bone marrow fibrosis on the response to erythropoietin in uremia
8. Role of iron metabolism in absorption and cellular uptake of aluminum
9. Inmune activation and the anaemia associated with chronic inflammatory disorders
10. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients
11. Optimizing erythropoietin therapy
12. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease
13. La polisulfona de alta permeabilidad mejora la respuesta de la anemia a la eritro-poyetina en hemodiálisis
14. Dialysis dose, membrane type, and anemia control
15. Cellular mechanism of resistance of erythropoietin
16. Anti-platelet therapy alters iron requirements in hemodialysis patients
17. Mechanisms of aluminum-induced microcytosis: Lessons from accidental aluminum intoxication
18. Los valores del Kt/v
19. Management of infections and cutaneous complications in vascular access
20. Iron, anemia and infection
21. Role of cytokines in the response to erythropoietin in hemodialysis patients
22. Iron metabolism in inflammation
23. Comparison of vascular access uses in the US and Europe: The Dialysis Outcomes and Practice Patterns Study (DOPPS)
24. National Kidney Foundation Dialysis Outcomes Quality Initiative